Effect of Cathepsin B Inhibitor CA-074Me on the Model of Mice Viral Myocarditis

ZHANG Xingang,ZHAO Gang,LI Shuangjie,LI Gaoping,CHEN Ruizhen,YANG Yingzhen
DOI: https://doi.org/10.3969/j.issn.1008-6358.2008.06.001
2008-01-01
Abstract:Objective:To observe the intervention effect of CA-074Me on the model of mouse viral myocarditis,and to explore the possible mechanism of its protection on myocardium.Methods:A total of 55 male 4-week-old BABL/c mice were randomly divided into 4 groups:normal control group(group N,n=10),viral myocarditis group(group V,n=15),CVB3 infected and low dose CA-074Me treated group(group L,n=15)and CVB3 infected and high dose CA074Me treated group(group H,n=15).Every mouse in the experimental group was given 0.1 ml coxsackie B3 virus intraperitoneally.At the same time,0.1 ml of normal saline was treated in group N.From day 2 to day 8,0.4mg/kg and 4mg/kg Ca-074Me were given intraperitoneally per day in group L and H mice respectively.On day 15 the serum was collected to detect cardiac troponin I(cTnI),then all of mice were sacrificed and hearts were removed for histologic study on day 15.Results:The cathepsin B expressional levels and serum cTnI levels were increased remarkably after CVB3 inoculation.In each of CA-074Me treatment groups,cTnI levels were markedly decreased,meanwhile,the myocardial damage was attenuated and mice survival rate was elevated compared with viral myocarditis group,especially high dose CA074Me group.Conclusion:CA074Me can attenuate the myocardium injury,and reduce the mortality of mouse with CVB3 myocarditis by inhibition of cathepsin B expression.And the relation between dose and effect is obvious in protecting the myocardium.The study may be a new method for treating viral myocarditis in the future.
What problem does this paper attempt to address?